Efinaconazole clinical trials
Also written Jublia and IDP-108.
How each study uses efinaconazole is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- 6 Jun 2014 · JUBLIA · NDA 203567 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
6 studies that test it; most in 2009 (2)
| Year | Studies |
|---|---|
| 2009 | 2 |
| 2015 | 2 |
| 2016 | 1 |
| 2017 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 2
University of Alabama at Birmingham (2) · Dow Pharmaceutical Sciences (2) · Bausch Health Americas, Inc. (1) · Dong-A ST Co., Ltd. (1)
Studies
Open first, then newest update. How each study uses efinaconazole is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- Safety and Pharmacokinetics of Efinaconazole Topical Solution in Subjects With Mild to Severe OnychomycosisCompletedPhase 4Bausch Health Americas, Inc.NCT02812771Written as EfinaconazoleHow we know
- Phase IV Clinical Trial to Evaluate the Efficacy and Safety of Jublia® in Mild to Moderate Toenail OnychomycosisCompletedPhase 4Dong-A ST Co., Ltd.NCT03280927Written as Jublia®How we know
- Real-World Evaluation of the Effect of Jublia on Nail PolishCompletedNot applicableUniversity of Alabama at BirminghamNCT03022916Written as Nail Polish + Efinaconazole SolutionHow we know
- Study Evaluating the Effect of Jublia on DermatophytomasCompletedPhase 4University of Alabama at BirminghamNCT03098615Written as Jublia (Efinaconazole 10% Topical Solution)How we know
- The Safety and Efficacy of Topical IDP-108 Versus Vehicle in Patients With OnychomycosisCompletedPhase 3Dow Pharmaceutical SciencesNCT01007708Written as IDP-108How we know
- Safety and Efficacy of Topical IDP-108 Versus Vehicle in Patients With OnychomycosisCompletedPhase 3Dow Pharmaceutical SciencesNCT01008033Written as IDP-108How we know
Given beside what is tested · 1 — efinaconazole is usual care or a partner of the new treatment
- Evaluating the Efficacy and Compatibility of Efinaconazole 10% Solution (Jublia) for the Treatment of Toenail Onychomycosis in Patients Wearing Toenail Polish Compared to Those Without PolishCompletedPhase 4University of Alabama at BirminghamNCT03110029Written as Efinaconazole 10% Topical Application Solution [JUBLIA]How we know
As the comparator · 1 — what is tested is compared with efinaconazole
Codes
What other systems call efinaconazole · ClinicalTrials.gg INT004364
- MeSH (NLM) C431707efinaconazoleConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) J82SB7FXWBEFINACONAZOLEConfirmed FDA, NLM, Wikidata
- RxNorm 1539753Confirmed FDA, Wikidata
- Wikidata Q21011225efinaconazoleConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C97998EfinaconazoleOne source FDA
- DrugBank DB09040One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C431707 | efinaconazole | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | J82SB7FXWB | EFINACONAZOLE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1539753 | — | Confirmed FDA, Wikidata |
| Wikidata | Q21011225 | efinaconazole | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C97998 | Efinaconazole | One source FDA |
| DrugBank | DB09040 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.